(Q35580011)

9 August 2017

title

Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy (English)

1 reference

9 August 2017

author

Martine Piccart-Gebhart

12

object named as

Martine Piccart-Gebhart

0 references

Kathrin Strasser-Weippl

1

object named as

Kathrin Strasser-Weippl

1 reference

9 August 2017

5

Bent Ejlertsen

1 reference

9 August 2017

4

Joyce O'Shaughnessy

1 reference

9 August 2017

11

Beverly Moy

1 reference

9 August 2017

7

Aman U Buzdar

1 reference

9 August 2017

Nora Horick

2

1 reference

9 August 2017

Ian E Smith

3

1 reference

9 August 2017

Frances Boyle

6

1 reference

9 August 2017

Pierre Fumoleau

8

1 reference

9 August 2017

William Gradishar

9

1 reference

9 August 2017

Miguel Martin

10

1 reference

9 August 2017

Kathleen I Pritchard

13

1 reference

9 August 2017

Deborah Lindquist

14

1 reference

9 August 2017

Erica Rappold

15

1 reference

9 August 2017

Dianne M Finkelstein

16

1 reference

9 August 2017

Paul E Goss

17

1 reference

9 August 2017

language of work or name

1 reference

16 April 2015

1 reference

9 August 2017

published in

Breast Cancer Research

1 reference

9 August 2017

volume

17

1 reference

9 August 2017

page(s)

56

1 reference

Creative Commons Attribution 4.0 International

9 August 2017

copyright license

start time

16 April 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s13058-015-0568-1

0 references

cites work

Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

Breast cancer in Brazil: present status and future goals

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

A penalized likelihood approach for arbitrarily censored and truncated data: application to age-specific incidence of dementia.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

Annual hazard rates of recurrence for breast cancer after primary therapy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4423419

A new look at the statistical model identification

26 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FS13058-015-0568-1

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2FS13058-015-0568-1

Time-dependence of hazard ratios for prognostic factors in primary breast cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25888246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25888246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Estrogen receptors and distinct patterns of breast cancer relapse

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25888246

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S13058-015-0568-1

1 reference

Dimensions Publication ID

9 August 2017

0 references

1 reference

9 August 2017

1 reference